5 September 2024
QV Bioelectronics secures £343,000 from Innovate UK’s Cancer Therapeutics programme to develop a new treatment for childhood brain tumours
• The project will adapt QV Bioelectronics’ existing electric field therapy (EFT) technology to develop the world’s first fully implantable EFT device to treat Diffuse Midline Glioma (DMG). • DMG is a highly aggressive childhood brain cancer and ultra-orphan disease with a...
3 September 2024
Infex Therapeutics to present RESP-X Phase I data at ERS Congress
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that Phase I data from RESP-X, the Company’s first-in-class anti-virulence antibody, will be presented in an oral presentation by Colm Leonard, Chief Clinical Officer at Infex, at...
27 August 2024
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
COPENHAGEN, Denmark, Aug. 26, 2024 /PRNewswire/ -- On 26 August – Cessatech A/S ("Cessatech" or "the Company") announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company which specialises in the...
22 July 2024
Oxford BioTherapeutics named 'Best Tech SME of the Year' at Thames Valley Tech & Innovation Awards 2024
Oxford, UK and San Jose, California, 22 July 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, announces it has been recognized as the ‘Tech SME of the Year’ at the sixth...
20 June 2024
Wirral footcare manufacturer Tectores steps into India
Footcare product manufacturer Tectores has shifted its manufacturing from China to India as part of an expansion drive. Wirral-based Tectores produces PelliTec, a product that helps prevent blisters forming on feet. It was developed by friends Karl Ormond and Lenny Waters who...
20 May 2024
Infex Therapeutics strengthens its senior leadership team
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it has appointed a new Director of Clinical Programmes, and promoted existing staff to strengthen its senior management team. Dr Kerry Nield has joined as Director of Clinical...
9 May 2024
Biofortuna completes acquisition of biological sample storage experts Cryoniss
Biofortuna Limited, the specialist laboratory services and CDMO, has completed the acquisition of Cryoniss Ltd, underlining its commitment to support life-changing research and development across the global biotech and life sciences sector. The acquisition of Cryoniss brings...
24 April 2024
CroBio announces completion of $1.55 million seed round
CroBio has announced the completion of $1.55 million seed round. The round was led by The Grantham Foundation for the Protection of the Environment, with participating investors – SOSV and Ponderosa Ventures, and with continued support from Catapult Ventures. Read the company...
22 April 2024
Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development
Manchester, UK, and Cambridge UK, 18 April 2024 - Monument Therapeutics, a precision neuroscience company, today announced new funding of £1.5 million from a combination of equity investment and non-dilutive grant as part of the Innovate UK Future Economy Investor Partnership...
9 April 2024
Maxwellia revolutionises menstrual health category in pharmacy with the introduction of Evana® and Ultravana®
Alderley Park, Cheshire, UK - April 08, 2024 - Women’s health champion Maxwellia is pleased to announce the availability of Evana® Heavy Period Relief 500mg tablets (tranexamic acid) and Ultravana® Period Pain Relief 250mg tablets (naproxen) to help women manage heavy and...